Market Overview

UPDATE: Oppenheimer Downgrades Body Central to Perform on on Lower Q4 Guidance

Related BODY
Body Central Issues Clarification on 1-for-10 Reverse Split, Effective Sept. 9th
30 Stocks Delisted So Far In 2014

Oppenheimer downgraded Body Central Corp. (NASDAQ: BODY) from Outperform to Perform.

Oppenheimer noted, "This morning, ahead of its participation at the ICR XChange Conference this Wednesday, January 16th, at 9:25 AM, BODY lowered 4Q EPS guidance to $0.10 (from $0.19-$0.22) and vs. Opco/consensus estimates of $0.28/$0.23. December proved to be especially challenging at the expense of margins and the turnaround is now taking longer to gain traction than initially expected. While we have confidence in the LT fundamentals and initiatives in place to support growth, we are stepping to the sidelines until we gain further visibility. Downgrading to Perform from Outperform and rescinding our price target."

Body Central closed at $9.71 on Monday.

Latest Ratings for BODY

DateFirmActionFromTo
Oct 2013Piper JaffrayMaintainsNeutral
Sep 2013Dougherty & CompanyDowngradesBuyNeutral
Jul 2013SunTrust Robinson HumphreyInitiates Coverage onNeutral

View More Analyst Ratings for BODY
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (BODY)

Around the Web, We're Loving...

Get Benzinga's Newsletters